The goal of this interventional study is to understand how the rhythmic abilities of individuals in the early stages of Parkinson's Disease (PD) are impacted by their levels of dopamine. The main questions it aims to answer are:
* Does dopamine shelter the ability to generate and maintain a regular tapping rhythm in the presence of disrupting sensory information?
* Does dopamine allow the adaptation of tapping speed in the presence of changing sensory information?
* Is the engagement of the motor system useful to improve the detection of changes in the tempo of sensory information?
Participants will be asked to perform a battery of simple rhythmic tasks On and Off medication to evaluate the effect of dopamine on their rhythmic skills.

开始日期2026-09-01

申办/合作机构

McMaster University

JPRN-UMIN000062079

/ Not yet recruitingN/AIIT

Research on the treatment of tic disorders and Tourette's syndrome with Chlorpromazine and LDOPA.

开始日期2026-08-01

申办/合作机构-

CTIS2026-526465-18-00

/ Not yet recruiting临床3期

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

开始日期2026-08-01

申办/合作机构

Region Hovedstadens Apotek

100 项与左旋多巴相关的临床结果

登录后查看更多信息

100 项与左旋多巴相关的转化医学

登录后查看更多信息

100 项与左旋多巴相关的专利（医药）

登录后查看更多信息

31,591

项与左旋多巴相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Advanced Parkinson’s disease treatment patterns in Italy: results from a multicenter observational study

Article

作者: Modugno, Nicola ; Ceravolo, Roberto ; Stocchi, Fabrizio ; De Pandis, Maria Francesca ; Barone, Paolo ; Lopiano, Leonardo ; Padovani, Alessandro ; Tessitore, Alessandro ; Pilleri, Manuela ; Zappia, Mario

BACKGROUND AND OBJECTIVES:

Substitution therapy with oral levodopa is the primary treatment of Parkinson's disease (PD). However, long-term levodopa use is associated with fluctuations in response and dyskinesia. These complications severely affect the patient quality of life. Fluctuation management in long-standing PD is poorly documented. The Parkinson's Disease Fluctuations treatment Pathway (PD-FPA) study was an Italian multicenter, observational study designed to describe how fluctuations are treated in patients with advanced disease.

PATIENTS AND METHODS:

Between July 2018 and December 2020, ten centres enrolled consecutive patients aged ≥18 years who had been diagnosed with PD 10-15 years before enrollment and had been experiencing fluctuations for at least 2 years before enrollment. Data on patient characteristics, PD stage, fluctuations, and treatments were collected at enrollment (T0) and prospectively at 6 months (T1) and 12 months (T2). Data were also collected retrospectively, at 1 and 2 years before T0.

RESULTS:

At T0, patients (n = 296, 60.1% male, mean age 68 years) had Hoehn and Yahr disease stage 2-3 and 47% had comorbidities (29.8% cardiovascular disease). PD stage and other PD assessment scores were overall stable during the entire 3-year observation period. Over 3 years, the use of dopamine agonists progressively decreased (51% of patients at T2), the use of monoamine oxidase-B inhibitors was stable (63%), while the use of catechol-O-methyltransferase inhibitors progressively increased (42%). Safinamide and opicapone showed the biggest increase in use over the 3-year observation period. Treatment changes were mostly prompted by fluctuations and were reported in about 50% of patients at T0 and 30% at T1 and T2.

CONCLUSION:

Maintenance of stable disease in patients with long-standing PD and fluctuations is feasible with non-invasive treatments. Accurate treatment adjustments and individualized strategies with new-generation add-on drugs may be of key importance.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada

Article

作者: Parra, Juan Carlos ; Boodhna, Trishal ; Belsey, Jonathan ; Ray Chaudhuri, K.

BACKGROUND:

The costs associated with advanced Parkinson's disease (aPD) extend beyond direct medical expenditure. As symptoms become more severe, professional and informal personal care costs are likely to exceed those incurred for medical and pharmacological treatment. The objective of this analysis is to explore the impact of treatment with subcutaneous foslevodopa/foscarbidopa (LDp/CDp) on the societal cost impact in the UK, France, Germany, Spain, and Canada.

METHODS:

A model was developed to aggregate expected costs incurred by a cohort with aPD over a 5-year time frame. Resource use for direct medical, non-medical, and informal care are estimated from a real world data source (Adelphi), mapped to the severity of disease as estimated by the extent of OFF-time experienced by patients. Indirect societal costs are estimated from published literature. Unit costs for each of the included countries are then applied to these resource use estimates. Symptom progression of individuals within the cohort are derived from a previously developed Markov model, which captures the differential effect on OFF-time of LDp/CDp versus best medical treatment (BMT).

RESULTS:

Overall costs for aDP patients were shown to rise over the 5-year time horizon, as symptom progression occurred. The use of LDp/CDp incurred greater drug costs than BMT, but, by delaying exacerbation of OFF-time, this additional cost was more than offset by other savings - principally attributable to professional and informal care. Aggregated results showed a net cumulative saving of €96,273 per patient over the 5 year time horizon. Results for the five individual countries evaluated ranged from €50,297 to €135,208 per patient saving.

CONCLUSION:

LDp/CDp has been shown to significantly improve OFF-time burden in patients with aPD, compared with BMT. Once the costs of professional and informal care are taken into account, the additional acquisition costs of LDp/CDp are more than offset, yielding a net societal saving.

2026-12-01·Synthetic and Systems Biotechnology

Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production in Corynebacterium glutamicum

Article

作者: Duan, Ran ; Jiang, Yan ; Zhang, Bin ; Wu, Xiaoyu ; Jia, Mengzhen ; Chu, Xiaohe ; Ye, Bangce ; Yang, Hui

ʟ-3,4-dihydroxyphenylalanine (ʟ-DOPA), the direct precursor of the neurotransmitter dopamine, is a cornerstone therapeutic agent for Parkinson's disease. In this study, Corynebacterium glutamicum was used as a microbial chassis to systematically evaluate its potential as a cell factory for ʟ-DOPA production. The strain was initially evaluated for ʟ-DOPA tolerance to confirm its suitability for production. Key hydroxylases, HpaB and HpaC, were introduced, and promoter and ribosome-binding site (RBS) optimization was applied to establish a de novo ʟ-DOPA biosynthetic pathway. To minimize flux toward competing branches, enzymes encoded by pheA and trpE2 were deleted, and fermentation conditions were optimized to balance cell growth with product formation. Promoter engineering was further employed to enhance the expression of Cgl0226, Cgl0218, and Cgl2101, thereby increasing the availability of the precursor ʟ-tyrosine for ʟ-DOPA biosynthesis. Additionally, deletion of competing shikimate pathway enzymes (encoded by qsuB and qsuD) combined with enhanced expression of aroA and aroC elevated carbon flux through the shikimate pathway. The final engineered strain, KD20, achieved an ʟ-DOPA titer of 710.9 ± 13.2 mg/L in shake-flask fermentation. Upon scale-up to a 5 L bioreactor under optimized conditions, the final titer reached 4605.58 ± 21.73 mg/L, representing the highest ʟ-DOPA yield reported in C. glutamicum. These results highlight the robust production capacity of C. glutamicum and underscore its strong potential for ʟ-DOPA biosynthesis.

1,463

项与左旋多巴相关的新闻（医药）

2026-08-01

·药时空

北大博士创业，半年融资7亿元

前言 2026年，对于士泽生物和其创始人李翔博士来说，是里程碑式的一年。年初，士泽生物连续完成B/B+轮及C1轮累计4亿元市场化融资；3月，又宣布完成合计约5亿元的C/C+轮融资。两笔加总，全年融资额超过7亿元。投资方阵容堪称豪华，中国国风投基金、三生制药、苏产投社保基金领衔，峰瑞资本、启明创投、礼来亚洲基金、红杉中国等老股东持续追加。在生物医药资本寒冬尚未完全退去的当下，这不仅仅是钱的问题，更是一张来自市场的信任票。但对于李翔而言，这7亿不过是他16年坚持的一个注脚。一从“养猪专业户”到干细胞追光者” 时间拉回到2006年。那一年，日本科学家山中伸弥刚刚发表iPSC（诱导多能干细胞）技术的首篇论文。彼时的李翔，还是华中农业大学动物科学专业的一名本科生，师从动物遗传育种顶级科学家。规划的人生是毕业后回四川老家开一个现代化分子育种养殖农场。改变他命运的，是舅舅的一场病。舅舅罹患帕金森病，手术治疗失败后失去了吞咽和语言能力。在与医生的交谈中，李翔第一次听说了干细胞疗法。一种理论上可以再生神经元、逆转帕金森病程的颠覆性技术。 “全球有超过1000万，中国有超过300万帕金森患者，”李翔后来在回忆中说。 “投身干细胞研究与产业化，不仅能够创造重大的社会价值，更可以帮助千万受苦难的病人家庭。” 为了跨专业闯入干细胞领域。他本科期间保持院系最优成绩，带队拿下国家级创新创业大赛全国一等奖，保送北大直接攻读博士，先后师从干细胞领域顶级科学家高绍荣教授和邓宏魁教授。北大博士毕业后，他又远赴美国威斯康星大学麦迪逊分校从事博士后研究，师从干细胞与神经细胞命运决定权威科学家Suchun Zhang。学术道路一片坦途之时，李翔却做了一个让许多人费解的决定：放弃教职，投身产业。他的逻辑冷静得近乎残酷，基础研究论文到上市新药的整体转化成功率可能不高于1%。“要做好这些事，必须要躬身入局。” 2021年，李翔带着一个书包、一个PPT和十几年专注干细胞的方向，在苏州BioBAY创办了士泽生物。他给自己的定位是“一杯水”：士泽生物需要我变成什么，我就变成什么。二 “现货型”细胞药的底层逻辑士泽生物所做的，是开发临床级、异体通用、“现货型”iPSC衍生神经细胞药。简单说，就是从健康供体获取体细胞，通过iPSC技术“返老还童”为多能干细胞，再定向分化为特定的神经细胞，批量制备后“现货”供应，移植到患者体内替代那些已经死亡的神经元。这不是传统意义上的“用药”，而是“换细胞”。帕金森病的病理核心是黑质多巴胺能神经元的渐进性丢失。现有的左旋多巴等药物只能补充多巴胺，随着病情进展终将失效而细胞替代性疗法，是从疾病机制层面恢复神经功能。李翔有一个形象的比喻：“如果将人体比作一棵不断向上发枝散叶的参天大树，干细胞就是树最底层的种子。” 这条技术路线的壁垒极高。从iPSC重编程、基因编辑，到定向分化、规模化制备，再到质量控制和临床转化，每一个环节都是“无人区”。士泽生物用了五年时间，自主建设了超过5000平方米的研发中心、B+A级GMP生产基地及质控中心。搭建了全流程的临床级制备工艺与质控体系，申请国内外发明专利三十余项。三九项批件与一个国家的战略背书截至2026年中，士泽生物已获得中国NMPA和美国FDA正式批准的9项中美注册临床试验批件。管线覆盖的适应症个个都是“硬骨头”：原发性帕金森病已推进至中国注册临床II期及美国注册临床I期；早发型帕金森病启动了中国首个随机双盲对照确证关键临床设计；帕金森型多系统萎缩于2026年开展注册临床试验；脊髓损伤是“全球首款”新药，已在中美开展注册临床I期；渐冻症同样实现了中美双报双批。 2025年，士泽生物的核心产品XS411注射液先后获得美国FDA和中国NMPA一次性无发补完全批准。 2026年7月，FDA又授予其快速通道资格认定。同月，由士泽生物牵头，联合同济大学、中国食品药品检定研究院、北京天坛医院、北京协和医院共同承担的“创新药物研发”国家科技重大专项正式启动。这是我国首个针对通用型iPSC衍生细胞新药治疗帕金森病的国家重大专项。从个人执念到国家战略，这条路李翔博士走了整整16年。结语在生物医药行业，人们习惯了用融资额、批件数、临床阶段来衡量一家公司的价值。但士泽生物的故事里，有一个更底层的逻辑：当一个人因为目睹亲人被疾病吞噬而选择了一条路，并且在这条路上坚持了16年。那么资本和政策的聚集，不过是水到渠成。 “士泽”二字，取自“国士无双”与“福泽病患”。李翔当年在北大图书馆画下的公司logo草图，正中心是一根拐杖，那是他舅舅帕金森病晚期时杵着的拐杖。如今，这根拐杖正在被一种叫iPSC的技术一寸一寸地扶正。 2026年的7亿融资，买的是时间，是产能，是通往关键性确证临床的入场券。但真正决定士泽生物能走多远的，从来不是钱，而是那个从2006年就开始转动、至今未曾停歇的命运齿轮。

2026-07-31

·网易号

士泽生物XS411 II期完成入组，iPSC细胞治疗迎关键节点

作者｜王云编辑｜于清7月30日，士泽生物医药有限公司（简称：士泽生物）宣布，其自主研发的异体通用“现货型”iPSC衍生多巴胺能神经前体细胞注射液XS411治疗原发性帕金森病的全国多中心注册II期临床试验，已顺利完成全部受试者入组。该试验采用PROBE设计，实现中美双报双批，国产iPSC细胞替代疗法进入关键验证阶段。实现中美双报双批本次临床试验由国家神经疾病医学中心——首都医科大学附属北京天坛医院牵头，冯涛教授担任主要研究者，联合北京协和医院、四川大学华西医院等多家国内顶尖医疗机构共同开展。本次研究最大亮点在于采用PROBE盲法评估设计（前瞻性、随机、开放标签、盲法终点评估）试验方案。相较于细胞治疗领域大量使用的单臂开放性试验，这套设计能有效降低评估偏倚，提升临床证据等级，为后续III期注册临床及药品上市申报提供高质量循证数据支撑，在国内神经领域iPSC临床中属于少见的高标准设计。作为国家科技重大专项支持品种，XS411先后获FDA与NMPA批准开展注册临床，实现中美双报双批。该产品区别于左旋多巴等传统药物以缓解运动症状为主的治疗模式，走的是对因治疗路线，即通过体细胞重编程得到iPSC，定向分化为高纯度多巴胺能神经前体细胞，经立体定向手术移植至患者脑部，旨在实现功能性神经细胞的再生与神经环路重建。前期I期随访数据显示，移植细胞可在脑内定植存活并合成多巴胺，受试者运动症状获得改善，安全性信号良好。现有药物需要持续服药、症状容易反复，细胞替代疗法有望实现长期疾病调控，正是这一前景，让全球资本持续盯着iPSC赛道。管线差异化布局士泽生物聚焦中枢神经退行性疾病，核心布局帕金森病、脊髓损伤、渐冻症等明确存在未满足临床需求的领域。公司选择了异体通用“现货型”iPSC细胞产品路线，与自体细胞治疗形成分化。自体iPSC方案需要为每位患者单独制备细胞，周期长、成本高；现货模式依托标准化iPSC种子细胞库批量生产、冻存备用，能大幅缩短患者等待周期，也是未来商业化实现普惠治疗的必经之路。硬件上，士泽生物已自主建设及运营超5000平方米研发中心、B+A级GMP基地，建立了全流程的临床级制备工艺及质量控制体系，具备多款细胞药物临床级规模化制备能力。资本上，士泽生物连续多年完成多轮融资，投资方包括红杉中国、礼来亚洲基金、启明创投、中国国风投基金等一线产业与财务资本，持续为临床推进和产能建设提供资金保障。放眼国内赛道，多家企业布局iPSC衍生多巴胺能细胞治疗帕金森病，产品陆续进入I/II期临床。相比同行，XS411具备国家级临床中心牵头、高标准随机盲法试验、中美双报三重优势，临床规范化程度排在行业前列。中国帕金森病患者数量庞大，现有治疗手段难以阻止病情持续进展，巨大的未满足临床需求为未来获批的细胞疗法预留了广阔市场空间。产品一旦顺利完成注册上市，将在国内开辟全新治疗赛道，商业化想象空间不小。仍需漫长周期iPSC细胞替代疗法被视作神经退行性疾病治疗的治疗方向，全球研发持续升温。日本同类产品已实现附条件上市，验证了该技术路径的商业化可行性。随着国内细胞药物监管体系逐步完善，再生医学创新药迎来发展窗口期。投资者与市场应当理性正视赛道潜藏的各类风险，避免对短期进展给予过高预期。II期完成全部受试者入组，仅仅意味着临床试验迈入随访阶段，产品最终的安全与有效结论依旧悬而未决。即便II期能够收获积极结果，后续还需要推进III期确证性试验，距离最终获批上市仍存在漫长周期。细胞移植疗法需要持续长期追踪致瘤隐患、免疫排斥反应以及移植物诱发异动症等各类不良事件，数年维度的随访结论，将会左右这款产品未来的发展空间。商业化落地同样横亘多重阻碍。细胞药物制备流程繁琐，质量管控标准严苛，短期内很难实现成本大幅下行。立体定向移植属于神经外科微创术式，对医疗机构硬件条件、医生实操水平具备较高门槛，短期内只能局限于头部三甲医院开展，大范围普及存在明显地域约束。与此同时，赛道研发热度持续攀升，海内外多条同方向管线同步推进，倘若产品顺利上市，即将直面白热化的行业竞争。疾病底层病理层面依旧存在尚未攻克的难题。帕金森病属于进展性病症，α-突触核蛋白相关病理进程或将持续侵害移植后的新生细胞，长期疗效能否稳定维持，依旧需要大量长期临床数据佐证。政策环境层面，细胞治疗药物的审评规范处于动态完善过程，监管尺度与申报标准发生调整，也有可能对整体研发进度形成扰动。综合来看，XS411 II期全部入组，标志着国产iPSC神经细胞疗法迈出关键一步。若后续临床试验顺利读出积极数据，有望重塑帕金森病治疗格局。需要注意的是，前沿生物技术投资高度依赖临床结果兑现，在正式疗效数据公布前，市场应当充分警惕预期过高带来的估值波动风险。敬告读者：本文基于公开资料信息或受访者提供的相关内容撰写，《全球财说》及文章作者不保证相关信息资料的完整性和准确性。无论何种情况下，本文内容均不构成投资建议。市场有风险，投资需谨慎！未经许可不得转载、抄袭！

2026-07-31

·BioSpace

AbbVie shares pressured as Q2 I&I beat falls below investor expectations

/ iStock, Rudzhan Nagiev AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected. While “a beat is a beat,” AbbVie’s shares faced pressure Friday after the immunology heavyweight reported exceeding consensus to a lesser extent than investors were anticipating. “AbbVie beat consensus expectations across its I&I portfolio, but beats were more modest than investors are typically accustomed to,” BMO Capital Markets wrote. This “may not be enough for ABBV investor high expectations.” Indeed, shareholders sent the company’s stock down nearly 4% to $247.50 in pre-market trading. ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); William Blair attributed the share decline to an update of earnings per share (EPS) guidance. The company shaved four cents off the range, which is now between $13.87 to $14.07. “We think that is misinterpreted given the net four-cent decline is due to the previously announced acquisition of Apogee,” William Blair wrote on Friday morning. AbbVie reported that its immunology and inflammation (I&I) portfolio beat consensus expectations by about 1% with total revenue of $8.79 billion, marking a 15% increase over the same period a year prior. Humira, once the best-selling drug in the world but now slipping off its patent cliff, beat by 3% with $756 million. Skyrizi notched $5.5 billion and Rinvoq $2.53 billion, marking beats of 1% and 2%, respectively. Immunology and inflammation AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis. May 20, 2026 · 2 min read · Tristan Manalac Read more “While the magnitude of Skyrizi and Rinvoq outperformance in the quarter will not fully quell fears of increasing competition, we believe they will continue to perform well and drive strong revenue growth for the company,” William Blair said. Overall, AbbVie recorded net revenue of $16.99 billion for the second quarter. While the I&I portfolio disappointed, AbbVie’s neurology programs impressed analysts, with a 4% beat. Led by schizophrenia and bipolar I disorder therapy Vraylar, the neuroscience unit recorded $3.23 billion. The Parkinson’s disease therapy Vyalev also impressed, with BMO noting “a faster launch than many analysts initially expected.” The drug took in $256 million for the quarter. Since the beginning of the year, AbbVie’s shares have increased 12% and the company has many meaningful catalysts to come, such as advancements for the Parkinson’s franchise, antibody-drug conjugate portfolio and additional indications for Skyrizi, William Blair wrote. AbbVie is awaiting a regulatory decision for tavapadon in Parkinson’s, which could help the company reach $5 billion in market potential for the disease area, according to Chief Commercial Officer Jeffrey Stewart. “There’s nothing else like it in the marketplace,” Stewart said on the Friday earnings call. The oral drug can be used alone or paired with standard of care carbidopa and levodopa. Clinical studies found that after 85 weeks of receiving tavapadon, more than 90% of patients did not need to up their dose of carbidopa and levodopa. AbbVie’s asset is also less prone to cause sedation, or “so-called sleep attacks,” according to Stewart. Phase 3 data has also shown a statistically significant improvement in motor and daily living complications at week 26. This has all led to excitement in the treatment community, which is aiding AbbVie’s confidence in the upcoming launch. The FDA is expected to render its decision by Dec. 31. Toward the end of the second quarter, AbbVie announced the $10.9 billion acquisition of Apogee Therapeutics . The deal is expected to bolster the pharma’s I&I portfolio, providing a rival to Sanofi and Regeneron’s blockbuster Dupixent. And AbbVie may not be done dealing. “We have ample financial capacity for more business development and remain focused on adding both early and late-stage opportunities across our core disease areas,” CEO Robert Michael said Friday morning. Earnings AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.” April 29, 2026 · 3 min read · Gabrielle Masson Read more

并购临床3期临床结果抗体药物偶联物

100 项与左旋多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00059	左旋多巴	N04BA01	DB01235

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	美国	Hoffmann-La Roche, Inc.	1970-06-04
帕金森病	美国	Shire Development LLC	1970-06-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
运动失调	临床3期	美国	AbbVie, Inc.	2009-06-01
运动失调	临床3期	德国	AbbVie, Inc.	2009-06-01
运动失调	临床3期	新西兰	AbbVie, Inc.	2009-06-01
哮喘	临床1期	美国	Acorda Therapeutics, Inc.	2015-12-01
吸烟	临床1期	美国	Acorda Therapeutics, Inc.	2015-12-01
自闭症谱系障碍	临床前	中国	复旦大学	2025-07-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05487300 (CTgov)	临床2/3期	直立性低血压 \| 帕金森病	40	Levodopa (Testing ON Levodopa)	構鏇鹹糧夢獵願齋選襯(齋構襯壓衊糧醖襯艱積) = 獵願選襯醖觸積膚鹽夢齋醖築範餘構鬱鏇醖襯 (憲遞壓夢襯範窪艱築範, 17.69) 更多	-	2024-12-05
				Levodopa (Testing Off Levodopa)	構鏇鹹糧夢獵願齋選襯(齋構襯壓衊糧醖襯艱積) = 範遞選齋齋選艱築築簾齋醖築範餘構鬱鏇醖襯 (憲遞壓夢襯範窪艱築範, 19.88) 更多
MDS2024	N/A	帕金森病	1,294	Continuous dopaminergic stimulation-based levodopa treatment	網艱糧製繭餘齋製顧獵(鬱淵糧願選餘獵積窪醖): MD = -0.69 更多	积极	2024-09-27
				Intermittent levodopa treatment
PD MED early disease randomisation (MDS2023)	N/A	帕金森病	1,593	Levodopa-sparing therapy (dopamine agonist or monoamine oxidase B inhibitor)	衊簾製觸顧憲糧簾膚夢(範淵遞壓窪壓膚簾顧觸): P-Value = 0.84 更多	积极	2023-08-27
				Levodopa alone
NCT03761030 (CTgov)	临床4期	癫痫持续状态 \| 重度抑郁症	51	L-DOPA (L-DOPA Arm)	鏇鹽襯顧鹽製築衊觸餘(膚構糧網製廠襯積鹽選) = 艱窪範衊蓋餘壓簾鹹襯壓齋糧繭鏇遞觸淵選鹽 (簾餘願積網製糧壓憲齋, 6.4) 更多	-	2023-05-22
				Placebo Oral Tablet (Placebo Arm)	鏇鹽襯顧鹽製築衊觸餘(膚構糧網製廠襯積鹽選) = 憲壓壓築構齋齋選淵繭壓齋糧繭鏇遞觸淵選鹽 (簾餘願積網製糧壓憲齋, 5.8) 更多
AAN2023	N/A	帕金森病	33	Intrajejunal Levodopa Infusion (ILI)	顧簾網蓋鹹觸構鏇醖淵(鑰遞憲鑰鏇遞廠範夢鹽) = Most common complications were PEG-J tube dislodgement and pump malfunction in 18 (54.5%) patients over the study period. 糧衊醖襯艱鹽醖遞淵遞 (鹹醖願蓋壓壓顧蓋繭製 ) 更多	-	2023-04-25
AAN2023	临床3期	帕金森病	-	CVT-301 84mg	鬱壓顧膚壓窪廠醖網積(鬱膚齋遞鬱鹹齋夢淵鹽) = 觸鹽壓淵餘簾窪齋製夢構製齋網窪觸襯鹹齋積 (淵窪鬱簾窪鏇鹹顧窪鑰 )	积极	2023-04-25
EAN2022	临床2期	帕金森病	24	Total daily LD/CD dose of 400/100 mg 4 intakes a day every 4 hours (Q4H) plus OPC 50 mg	網齋構製餘壓糧齋鏇鬱(製憲糧鬱蓋願衊艱糧廠) = The Q3H plus OPC regimen was also associated with an increase in LD Cmin with no significant impact on LD Cmax, leading to a ~60–90% decrease in the LD fluctuation (variation between Cmax and Cmin) 選齋鑰築構鏇壓構壓醖 (鹹遞築範蓋構膚淵餘範 ) 更多	积极	2022-06-24
				Total daily LD/CD dose of 400/100 mg 5 intakes a day every 3 hours (Q3H) plus OPC 50 mg
CVT-301 (MDS2021)	临床3期	帕金森病	709	CVT-301 84 mg	網醖鹽夢蓋衊壓製觸衊(鏇顧簾築築製鑰夢觸網) = More patients achieved and maintained an ON state within 60 minutes postdose vs placebo 積憲積繭鏇醖繭淵製夢 (窪製繭窪糧選製觸廠鏇 ) 更多	积极	2021-09-17
				Placebo
NCT01118520 (AARDVARK, CTgov)	临床2期	腹主动脉瘤	224	perindopril arginine (Perindopril)	遞蓋齋鏇艱夢顧繭網鏇(獵簾齋醖鏇糧鹽築壓願) = 襯遞顧夢齋夢蓋構鹹餘壓鑰衊觸願獵製窪鏇憲 (鏇糧餘餘壓積鹹憲艱齋, 0.02) 更多	-	2021-01-26
				amlodipine 5mgs (Amlodipine)	遞蓋齋鏇艱夢顧繭網鏇(獵簾齋醖鏇糧鹽築壓願) = 鏇築構廠膚積築膚範鏇壓鑰衊觸願獵製窪鏇憲 (鏇糧餘餘壓積鹹憲艱齋, 0.02) 更多
MDS2020	N/A	帕金森病一线	360	Levodopa	顧窪簾鏇網襯窪蓋遞選(糧構範廠蓋觸鹽憲鏇網) = 襯憲衊觸膚衊積衊鬱鬱膚鬱鹽糧構糧齋鏇餘網 (蓋範襯淵積糧積蓋廠壓, 3 ~ 15.49)	积极	2020-09-12